Modified natural killer cells having increased cytotoxicity and greater survival

The present invention relates to variants of genetic modification of NK cells (natural killer cells) to increase their cytotoxicity and increase their survival, for improving therapeutic activity of NK cell. Also disclosed is a composition DNA fragments of Fas-ligand (APTL; FASL; CD178; CD95L; ALPS1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Beletsky, Igor, Glukhova, Xenia
Format:	Patent
Sprache:	eng ; fin ; swe
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to variants of genetic modification of NK cells (natural killer cells) to increase their cytotoxicity and increase their survival, for improving therapeutic activity of NK cell. Also disclosed is a composition DNA fragments of Fas-ligand (APTL; FASL; CD178; CD95L; ALPS1B; CD95-L; TNFSF6; TNLG1A; APT1LG1) and methods for obtaining NK cells with increased Fas-ligand production. The invention encompasses also compositions of engineered NK cells and NK cell lines and uses thereof. Keksintö koskee NK-solujen (luonnolliset tappajasolut) geneettisten modifikaatioiden variantteja, NK-solujen sytotoksisuuden lisäämiseksi ja eloonjäännin pidentämiseksi, niiden terapeuttisen aktiivisuuden parantamiseksi. Lisäksi esitetään Fas-ligandin (APTL; FASL; CD178; CD95L; ALPS1B; CD95-L; TNFSF6; TNLG1A; APT1LG1) DNA-fragmenttikoostumus ja menetelmiä NK-solujen saamiseksi, joilla NK-soluilla on lisääntynyt Fas-ligandin tuotanto. Keksintö kattaa myös muunnettujen NK-solujen ja NK-solulinjojen koostumuksia, sekä niiden käyttöjä.